Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration

Core Viewpoint - Repare Therapeutics Inc. has entered into a definitive asset purchase agreement with Gilead Sciences, Inc. for the acquisition of its polymerase theta (Pol) ATPase inhibitor, RP-3467, indicating a strategic collaboration in oncology research and development [1] Company Summary - Repare Therapeutics Inc. is a clinical-stage precision oncology company focused on developing innovative cancer therapies [1] - The acquisition of RP-3467 by Gilead is expected to enhance Gilead's oncology portfolio, leveraging its expertise in the field [1] Industry Summary - The oncology research and development sector is witnessing significant consolidation, as companies seek to combine resources and expertise to advance cancer treatment options [1] - The transaction highlights the growing interest in precision oncology and the potential for best-in-class therapies in the market [1]